In the discovery stages, which step follows Define Lead?

• A. Define Target
• B. Refine and Formulate Lead
• C. Optimize Lead
• D. Prove Safety and Efficacy

Answer: (C)

In drug discovery, after you have defined a lead, the next step is to optimize that lead. This means carefully tweaking the chemical structure to improve how strongly and selectively it hits the target, while also refining properties that affect how the drug behaves in the body. You’re aiming for higher potency, better selectivity to minimize off-target effects, and improved drug-like characteristics such as solubility, stability, and oral bioavailability. At the same time, you assess metabolic stability and potential safety liabilities, balancing efficacy with a favorable pharmacokinetic profile and safety margin. This process is iterative, using structure–activity relationships, in vitro and ADME data, and sometimes in silico models to guide modifications. Only after achieving a lead with robust activity, good pharmacokinetics, and acceptable safety considerations do you advance to preclinical development. Proving safety and efficacy is addressed later, during preclinical toxicology and clinical trials, and defining the target is an earlier discovery step. Refining a lead is part of optimization, but the standard next move is to optimize the lead.